Price of key drug rose by 12,000 per cent, British probe finds

Authorities in Britain and US step up pressure on drug firms over prices

16th December, 2016
CMA crackdown on drug pricing. Pic:iStock

In Britain, the country’s main competition body, the Competition and Markets Authority (CMA) has been cracking down on excessive prices being charged to the country’s National Health Service (NHS).

This morning, it announced the provisional findings of an investigation into the price charged by a company called Actavis UK for hydrocortisone tablets, which are used to treat life-threatening conditions such as Addison’s disease.

The CMA said Actavis UK had...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Analysis: Variants and vaccines make projecting path of virus more complex

Health Rachel Lavin 3 hours ago

HSE’s latest private hospitals Covid deal estimated to cost €47 million a month

Health Daniel Murray 4 days ago

Key public health posts remain vacant

Health Daniel Murray 4 days ago

Breakdown of HSE’s €1.6 billion war chest to fight Covid-19

Health Daniel Murray 4 days ago